The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict DR Horton's revenues will increase 25.7% and EPS will expand 172.7%.
The average estimate for revenue is $1.38 billion. On the bottom line, the average EPS estimate is $0.30.
Last quarter, DR Horton tallied revenue of $1.15 billion. GAAP reported sales were 15% higher than the prior-year quarter's $999.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.20. GAAP EPS of $2.21 for Q3 were much higher than the prior-year quarter's $0.09 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 18.7%, 190 basis points better than the prior-year quarter. Operating margin was 6.8%, 140 basis points better than the prior-year quarter. Net margin was 68.5%, 6,560 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $4.38 billion. The average EPS estimate is $0.69.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 576 members out of 1,143 rating the stock outperform, and 567 members rating it underperform. Among 324 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 153 give DR Horton a green thumbs-up, and 171 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DR Horton is hold, with an average price target of $17.98.
- Add DR Horton to My Watchlist.